Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.
Wu Y, Terekhanova NV, Caravan W, Naser Al Deen N, Lal P, Chen S, Mo CK, Cao S, Li Y, Karpova A, Liu R, Zhao Y, Shinkle A, Strunilin I, Weimholt C, Sato K, Yao L, Serasanambati M, Yang X, Wyczalkowski M, Zhu H, Zhou DC, Jayasinghe RG, Mendez D, Wendl MC, Clark D, Newton C, Ruan Y, Reimers MA, Pachynski RK, Kinsinger C, Jewell S, Chan DW, Zhang H, Chaudhuri AA, Chheda MG, Humphreys BD, Mesri M, Rodriguez H, Hsieh JJ, Ding L, Chen F. Wu Y, et al. Among authors: pachynski rk. Nat Commun. 2023 May 17;14(1):2817. doi: 10.1038/s41467-023-38561-y. Nat Commun. 2023. PMID: 37198186 Free PMC article. No abstract available.
PACT: a pipeline for analysis of circulating tumor DNA.
Webster J, Dang HX, Chauhan PS, Feng W, Shiang A, Harris PK, Pachynski RK, Chaudhuri AA, Maher CA. Webster J, et al. Among authors: pachynski rk. Bioinformatics. 2023 Aug 1;39(8):btad489. doi: 10.1093/bioinformatics/btad489. Bioinformatics. 2023. PMID: 37549060 Free PMC article.
Epigenetic regulation during cancer transitions across 11 tumour types.
Terekhanova NV, Karpova A, Liang WW, Strzalkowski A, Chen S, Li Y, Southard-Smith AN, Iglesia MD, Wendl MC, Jayasinghe RG, Liu J, Song Y, Cao S, Houston A, Liu X, Wyczalkowski MA, Lu RJ, Caravan W, Shinkle A, Naser Al Deen N, Herndon JM, Mudd J, Ma C, Sarkar H, Sato K, Ibrahim OM, Mo CK, Chasnoff SE, Porta-Pardo E, Held JM, Pachynski R, Schwarz JK, Gillanders WE, Kim AH, Vij R, DiPersio JF, Puram SV, Chheda MG, Fuh KC, DeNardo DG, Fields RC, Chen F, Raphael BJ, Ding L. Terekhanova NV, et al. Nature. 2023 Nov;623(7986):432-441. doi: 10.1038/s41586-023-06682-5. Epub 2023 Nov 1. Nature. 2023. PMID: 37914932 Free PMC article.
Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).
Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM; SPOTLIGHT Study Group. Jani AB, et al. J Urol. 2023 Aug;210(2):299-311. doi: 10.1097/JU.0000000000003493. Epub 2023 Apr 26. J Urol. 2023. PMID: 37126069
[No title available]
[No authors listed] [No authors listed] PMID: 37785254
Reply by Authors.
Crawford ED, Garnick MB, Eckel RH, Miner MM, Freedland SJ, Pachynski RK, Wassersug RJ, Rosenberg MT, Walker LM, Fairman C, Curley T, Crosby M, Lin PH, Hafron JM. Crawford ED, et al. Among authors: pachynski rk. Urol Pract. 2024 Jan;11(1):30-31. doi: 10.1097/UPJ.0000000000000473.02. Epub 2023 Nov 6. Urol Pract. 2024. PMID: 38051218 No abstract available.
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.
Luke JJ, Gelmon K, Siu LL, Moreno V, Desai J, Gomez-Roca CA, Carlino MS, Pachynski RK, Cosman R, Chu QS, Damian S, Curigliano G, Tam R, Wang X, Jeyamohan C, Wang L, Zhu L, Santucci-Pereira J, Greenawalt DM, Tabernero J. Luke JJ, et al. Among authors: pachynski rk. Clin Cancer Res. 2024 Dec 13. doi: 10.1158/1078-0432.CCR-24-0439. Online ahead of print. Clin Cancer Res. 2024. PMID: 39670852
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial.
Choueiri TK, Kuzel TM, Tykodi SS, Verzoni E, Kluger H, Nair S, Perets R, George S, Gurney H, Pachynski RK, Folefac E, Castonguay V, Lee CH, Vaishampayan U, Miller WH Jr, Bhagavatheeswaran P, Wang Y, Gupta S, DeSilva H, Lee CW, Escudier B, Motzer RJ. Choueiri TK, et al. Among authors: pachynski rk. ESMO Open. 2024 Dec;9(12):104073. doi: 10.1016/j.esmoop.2024.104073. Epub 2024 Dec 5. ESMO Open. 2024. PMID: 39642635 Free PMC article. Clinical Trial.
58 results